Filter By Industry
Filter By Tag

Newsroom

NuvOx Pharma Press releases

1 - 8 of 8 Press Releases

Jan 23, 2017
NuvOx Pharma LLC and Jiangsu Nhwa Pharmaceutical Co., Ltd. (SZSE: 002262) have signed a licensing agreement for the exclusive development and sales of NVX-408 for China for treating hemorrhagic shock and perioperative blood loss.

Nov 01, 2016
NuvOx Pharma has been awarded a grant from the National Cancer Institute for $298,820.00 entitled, "B7-H3-Targeted Contrast Agent for Ultrasonic Imaging of Breast Cancer".

Aug 25, 2016
NuvOx Pharma, a clinical stage biotechnology company, has been awarded a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the National Institutes of Health for $243,164.00 entitled, "Fibrin...

Aug 18, 2016
Evan Unger, MD, President and CEO of NuvOx, announced that the FDA has allowed an investigational new drug application (IND) for NVX-208 (dodecafluoropentane emulsion) to be tested in a Phase Ib trial in stroke patients.

May 26, 2016
Evan Unger, MD, President and CEO of NuvOx Pharma, a Tucson based biotechnology company, announced that the company has been awarded a grant from the National Cancer Institute to develop an ultrasound contrast agent to diagnose pancreatic cancer.

Feb 12, 2016
Tucson based pharmaceutical company NuvOx Pharma announced today that it has secured orphan drug designation from the FDA for its investigational drug NVX-508 for vaso-occlusive crisis (VOC) and acute chest syndrome (ACS) in sickle cell disease.

Feb 11, 2016
The FDA has notified NuvOx Pharma that it may proceed with a clinical trial for its Investigational New Drug (IND), NVX-508 for vaso-occlusive crisis (VOC) and acute chest syndrome (ACS) in sickle cell disease.

Dec 04, 2015
Tucson based pharmaceutical company NuvOx Pharma announced today that it has secured orphan drug designation from the FDA for its investigational radiosensitizer for glioblastoma multiforme.


NuvOx Pharma RSS Feed